14344-48-0

Basic information

• Product Name: EC
• Synonyms: N,N'-1,2-ETHYLENEBIS-L-CYSTEINE;L,L-ETHYLENEDICYSTEINE;L-CYSTEINE, N,N'-1,2-ETHANEDIYLBIS-;N,N'-Ethylenedi-L-cysteine;N,N'-1,2-Ethanediylbis-L-cysteine
• CAS NO: 14344-48-0
• Molecular Formula: C₈H₁₆N₂O₄S₂
• Molecular Weight: 268.35
• Mol File: 14344-48-0.mol

Chemical Properties

• Melting Point: 245-246℃
• Boiling Point: 467.8°Cat760mmHg
• Flash Point: 236.7°C
• Appearance: /
• Density: 1.366
• Vapor Pressure: 4.78E-10mmHg at 25°C
• Refractive Index: 1.577
• CAS DataBase Reference: EC(CAS DataBase Reference)
• NIST Chemistry Reference: EC(14344-48-0)
• EPA Substance Registry System: EC(14344-48-0)

Safety Data

• Hazardous Substances Data: 14344-48-0(Hazardous Substances Data)

Usage

Chemical Properties

Colourless solid

InChI:InChI=1/C8H16N2O4S2/c11-7(12)5(3-15)9-1-2-10-6(4-16)8(13)14/h5-6,9-10,15-16H,1-4H2,(H,11,12)(H,13,14)

Upstream product

• 34592-47-7 L-thioproline 
• 444-27-9 L-thiaproline 
• 14344-59-3 S,S'-bis-benzyl ethylene-bis-L-cysteine 

Downstream Products

• 246039-26-9 S,S'-bis-benzyl-N,N'-bis-benzyloxycarbonyl ethylene bis-L-β-homocysteine 
• 246039-25-8 S,S'-bis-benzyl-N,N'-bis-benzyloxycarbonyl ethylene bis-L-β-homocysteine dimethylester 
• 246039-24-7 S,S'-bis-benzyl-N,N'-bis-benzyloxycarbonyl ethylene bis-L-cysteinoyl diazomethane 
• 246039-23-6 S,S'-bis-benzyl-N,N'-bis-benzyloxycarbonyl ethylene-bis-L-cysteine 
• 14344-59-3 S,S'-bis-benzyl ethylene-bis-L-cysteine 

Related news

EU DEMO EC (cas 14344-48-0) system preliminary conceptual design08/10/2019

The engineering design and R&D of auxiliary heating systems and their sub-systems are a key activities in the frame of the present conceptual design phase for a first of a kind DEMOnstration Fusion Power Plant in order to develop a system capable of achieving and controlling burning plasmas. In ...detailed

Design of the ITER EC (cas 14344-48-0) upper launcher nuclear shielding08/09/2019

ITER will be equipped with four EC (Electron Cyclotron) Upper Launchers (UL) of 8 MW microwave power each with the aim to counteract plasma instabilities during operation. These launcher antennas will be installed into four upper ports of the ITER vacuum vessel. Beside their functional purpose t...detailed

Heteroscedastic stratified two-way EC (cas 14344-48-0) models of single equations and SUR systems08/06/2019

A relevant issue in panel data estimation is heteroscedasticity, which often occurs when the sample is large and individual units are of varying size. Furthermore, many of the available panel data sets are unbalanced in nature, because of attrition or accretion, and micro-econometric models appl...detailed

Demonstration of synchronous control of EC (cas 14344-48-0) TL switch and gyrotron for ITER EC (cas 14344-48-0) system08/05/2019

The ITER EC system includes both an equatorial port launcher and upper port launchers as RF power injection devices, The waveguide switch in the transmission line (TL) is used to select the operating launcher. Its operation is required even during plasma operation, primarily for the mid-pulse sw...detailed

Enhanced operation of the Eu EC (cas 14344-48-0) test facility08/04/2019

A Test Facility (TF) has been designed and installed at SPC to allow for the commissioning of the EU gyrotrons developed in view of their integration to the ITER EC system. The first phase of operation of this TF was dedicated to the development of the EU 2 MW coaxial cavity gyrotron [1,2].The E...detailed

Relevant articles and documents

Synthesis and characterization of novel benzovesamicol analogs

Three new racemic vesamicol analogs were successfully prepared in good yields and high purity. All compounds were characterized by both IR and NMR spectroscopy. Compounds (±)-5 and (±)-6 showed a moderate lipophilicity compared with reference compounds IBVM and DRC140, respectively. However, the lipophilicity of DRC140 and (±)-9 showed very similar behaviors. TUeBITAK.

Radiochemical synthesis and preliminary evaluation of anti-bladder cancer monoclonal antibody BDI-1 labeled with rhenium-188

The anti-human bladder cancer monoclonal antibody BDI-1 was radio-labeled with rhenium-188 by direct labeling methods using SnCl2 as reductant and MDP as stannous stabilizer or by indirect method using NHS-ECM ester as bifunctional chelator. Radiochemical yields of 30 ± 7.23% and 87.4 ± 5.67% and radiochemical purity of more than 95% were achieved. The inmmunoreactive fraction was 58.7%. The results showed that radionuclide 188Re might be employed using the same labeling methodology with 99mTc labeling of BDI-1 for radiommunoimaging (RII) and radioimmunotherapy (RIT) and that may be useful in radioimmunodetection and RIT of human bladder carcinoma in vivo. Copyright

Synthesis and characterization of the copper(ii) complexes of new N 2S2-donor macrocyclic ligands: Synthesis and in vivo evaluation of the 64Cu complexes

The aim of this work was to prepare a novel class of 64Cu(ii) labeled complexes with the new macrocyclic ligands 1,10-dithia-4,7- diazacyclododecane-3,8-dicarboxylic acid (NEC-SE, 1), 1,10-dithia-4,7- diazacyclotridecane-3,8-dicarboxylic acid (NEC-SP, 2) and 1,10-dithia-4,7- diazacyclotetradecane-3,8-dicarboxylic acid, (NEC-SB, 3) to evaluate the usefulness of these macrocycles for potential utility as 64Cu(ii) chelators. The corresponding non-radioactive complexes [Cu(NEC-SE)] ·3H2O (4), [Cu(NEC-SP)]·3H2O (5) and [Cu(NEC-SB)] (6) were prepared and their 64Cu-analogs, [ 64Cu(NEC-SE)] (7) and [64Cu(NEC-SP)] (8) and [ 64Cu(NEC-SB)] (9) were produced in >98% radiochemical purity. Rats were injected with complex 7, 8 or 9 and were euthanized at 1, 4 and 24 h. All three complexes are cleared from the blood over the first hour following injection but there is poor clearance of this activity over 24 h. A similar pattern of retention was noted in the liver where the levels of activity in this tissue at 1 h are not statistically different from those at 24 h. Molecular mechanics and DFT studies were performed on the complexes in order to gain insight into the lower stability. The Royal Society of Chemistry 2009.

METHOD OF ENCAPSULATING METAL COMPLEX WITHIN LIPOSOMES

An object of the present invention is to provide a method of producing liposome wherein a complex of a short half-life metallic radioactive nuclide such as 99mTc and CD is encapsulated, with radiochemical yield and purity enabling practical application. The present invention provides a method of producing a liposome wherein a complex of a short half-life metallic radioactive nuclide and ethylenedicysteine (CD) is encapsulated, which comprises mixing a complex of a short half-life metallic radioactive nuclide and N-[2-(1H-pyrrolylmethyl)]-N'-(4-penten-3-on-2)-ethane-1,2-diamine with an ethylenedicysteine (CD)-encapsulated liposome, and incubating the mixture.